An Open Clinical Study on the Safety and Efficacy of Autologous GD2-CAR T Cells in the Treatment of Relapsed Refractory Neuroblastoma
Latest Information Update: 26 Dec 2024
Price :
$35 *
At a glance
- Drugs Anti GD2 chimeric antigen receptor T cell therapy Yake Biotechnology (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- 20 Nov 2024 New trial record